Subsequently, Scarborough et al. [81] completed a pre-clinical evaluation of a tankyrase inhibitor, AZ1366, in combination with EGFR-specific TKIs in EGFR mutant lung cancer cell lines. The gene discussed is EGFR; the disease is lung carcinoma.